Brief Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advancedat a late stage, far along tumors.
Intervention / Treatment
- Drug: MDX2004
Inclusion Criteria:
- Participant must be ≥ 18 years of age.
- Histologically or cytologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of locally advanced or metastatic malignancy.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 or 1.
- All participants should have at least 1 measurable site of disease according to RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion.
- Adequate hematologic, hepatic and renal function.
- All contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..